A CTC blood test has the advantage of being minimally invasive thus enabling us to obtain a second blood sample from an ER-positive breast cancer patient who appeared to have lost all ER expression in her CK7-positive/Hoechst-positive CTCs. The gene discussed is KRT7; the disease is breast carcinoma.